supp.fit

Vitamin K: study protocols

168 study groups say how much Vitamin K participants took a day. These are the doses the studies gave. They are not a recommendation.

Vitamin K: what the research found →

Dose per serving from products

4,480 products in our catalogue print how much Vitamin K a serving holds.

Most common: 50 mcg to 100 mcg, 34% of 4,480 products.

Dose per servingProducts
10 mcg or less
206
10 mcg to 25 mcg
675
25 mcg to 50 mcg
950
50 mcg to 100 mcg
1,528
100 mcg to 250 mcg
708
250 mcg to 500 mcg
122
500 mcg to 1 mg
131
over 1 mg
160

Dose per serving from research

168 study groups in 119 studies say how much Vitamin K participants took a day.

These are the doses the studies gave. They are not a recommendation.

Most common: 25 mg to 50 mg, 18% of 168 study groups.

Daily doseStudy groups
25 mcg or less
8
25 mcg to 50 mcg
9
50 mcg to 100 mcg
24
100 mcg to 250 mcg
28
250 mcg to 500 mcg
24
500 mcg to 1 mg
21
1 mg to 2.5 mg
11
2.5 mg to 5 mg
5
5 mg to 10 mg
4
10 mg to 25 mg
4
25 mg to 50 mg
30

Commonly used together

47 of 168 study groups took Vitamin K with something else. Shown: what 3 or more different studies gave.

What was given together, not what works together.

Taken withStudy groups
Vitamin D
36
Calcium
26
Vitamin D3
5
Vitamin B12
3
Zinc
3

168 study groups

Study
Menaquinone-7 as a novel pharmacological therapy in the treatment of rheumatoid arthritis: A clinical study
2015 · MK-7 treated group · Adults with rheumatoid arthritis; 24 male and 60 female across the study, average age 47.2 years
100 mcg90 days42
Comparison of concurrent treatment with vitamin K(2) and risedronate compared with treatment with risedronate alone in patients with osteoporosis: Japanese Osteoporosis Intervention Trial-03
2017 · risedronate and vitamin K2 group · Women aged 65 years or older with osteoporosis
45 mg2 years931
Vitamin K2 (menatetrenone) effectively prevents fractures and sustains lumbar bone mineral density in osteoporosis
2000 · vitamin K2-treated group · Patients with osteoporosis; age and sex not reported
45 mg2 years120
Effect of menatetrenone, a vitamin k2 analog, on recurrence of hepatocellular carcinoma after surgical resection: a prospective randomized controlled trial
2012 · MNT group · Patients undergoing curative hepatectomy for primary hepatocellular carcinoma
45 mg—50
Anticancer effects of vitamin K combined with transarterial chemoembolization in hepatocellular carcinoma, a randomized controlled trial
2025 · TACE + vitamin K group · Adults aged 18–89 with unresectable hepatocellular carcinoma
45 mg4 weeks50
The effect of menatetrenone, a vitamin K2 analog, on disease recurrence and survival in patients with hepatocellular carcinoma after curative treatment: a pilot study
2006 · menatetrenone group · Patients diagnosed as free of hepatocellular carcinoma after surgical resection or percutaneous local ablation
45 mg3 years32
Preventive effects of vitamin K on recurrent disease in patients with hepatocellular carcinoma arising from hepatitis C viral infection
2007 · vitamin K2 group · Patients with hepatitis C virus infection and hepatocellular carcinoma, free of disease after radiofrequency ablation or surgery
45 mg—30
Efficacy and safety of sorafenib plus vitamin K treatment for hepatocellular carcinoma: A phase II, randomized study
2021 · Sorafenib + vitamin K · Adults aged 18–85 with advanced hepatocellular carcinoma
45 mg—22
Combination of vitamin K2 and angiotensin-converting enzyme inhibitor ameliorates cumulative recurrence of hepatocellular carcinoma
2009 · VK single treatment · Patients after curative therapy for hepatocellular carcinoma; age and sex not reported
45 mg1461 days—
Combination of vitamin K2 and angiotensin-converting enzyme inhibitor ameliorates cumulative recurrence of hepatocellular carcinoma
2009 · Combination treatment with VK and ACE-I · Patients after curative therapy for hepatocellular carcinoma; age and sex not reported
45 mg1461 days—
The prevention of hip fracture with menatetrenone and risedronate plus calcium supplementation in elderly patients with Alzheimer disease: a randomized controlled trial
2011 · menatetrenone group · elderly patients with Alzheimer disease and hypovitaminosis K and D
45 mg1 year—
Menaquinone-7 supplementation improves arterial stiffness in healthy postmenopausal women. A double-blind randomised clinical trial
2015 · MK-7 · Healthy postmenopausal women
180 mcg3 years120
Vitamin K2 in Managing Nocturnal Leg Cramps: A Randomized Clinical Trial
2024 · vitamin K2 · Adults aged 65 years and older with at least 2 documented nocturnal leg cramp episodes during the 2-week screening period
180 mcg8 weeks103
Effect of vitamin K2 administration on depression status in patients with polycystic ovary syndrome: a randomized clinical trial
2022 · intervention group (vitamin-administered arm) · Women aged 18–40 with polycystic ovary syndrome
90 mcg8 weeks42
Vitamin K-induced effects on body fat and weight: results from a 3-year vitamin K2 intervention study
2018 · vitamin K2 (MK-7) group · Postmenopausal women aged 55–65 years
180 mcg3 years—
Association of vitamin K status with adiponectin and body composition in healthy subjects: uncarboxylated osteocalcin is not associated with fat mass and body weight
2012 · menaquinone-4 group · Postmenopausal women
45 mg3 years164
Effect of Menaquinone-7 Supplementation on Arterial Stiffness in Chronic Hemodialysis Patients: A Multicenter Randomized Controlled Trial
2023 · Treatment group (oral MK-7) · Adults aged 18 years or older receiving maintenance hemodialysis, with carotid-femoral pulse wave velocity (cfPWV) of at least 10 m/s
375 mcg24 weeks50
Vitamin K2 as a potential therapeutic candidate for the prevention of muscle cramps in hemodialysis patients: A prospective multicenter, randomized, controlled, crossover pilot trial
2022 · Vitamin K2 · Adults with maintenance hemodialysis and muscle cramps refractory to conventional interventions; age and sex not reported
360 mcg4 weeks39
Two-year randomized controlled trial of vitamin K1 (phylloquinone) and vitamin D3 plus calcium on the bone health of older women
2007 · vitamin K1 · Healthy, nonosteoporotic Scottish women aged 60 years or older
200 mcg2 years—
Three-year low-dose menaquinone-7 supplementation helps decrease bone loss in healthy postmenopausal women
2013 · MK-7 · Healthy postmenopausal women; age not reported
180 mcg3 years—
Effect of Low-Dose Vitamin K2 Supplementation on Bone Mineral Density in Middle-Aged and Elderly Chinese: A Randomized Controlled Study
2020 · 50 µg/day group · Community-dwelling men and postmenopausal women aged 50–75 years
50 mcg1 year—
Effect of Low-Dose Vitamin K2 Supplementation on Bone Mineral Density in Middle-Aged and Elderly Chinese: A Randomized Controlled Study
2020 · 90 µg/day group · Community-dwelling men and postmenopausal women aged 50–75 years
90 mcg1 year—
Effects of maternal micronutrient supplementation on fetal loss and infant mortality: a cluster-randomized trial in Nepal
2003 · Multiple micronutrients · Pregnant women in rural Nepal
64 mcg——
Vitamins K2 and D3 Improve Long COVID, Fungal Translocation, and Inflammation: Randomized Controlled Trial
2025 · vitamin K2/D3 arm · Adults aged 18 years or older with at least two moderate-intensity long COVID symptoms persisting for at least three months after COVID-19 infection
240 mcg24 weeks98
Comparison of cheese with and without Propionibacterium freudenreichii subsp. shermanii LMGT 2951 on off-season muscle strength and VO(2) max development in Nordic skiers: a randomized clinical trial
2025 · Jarlsberg group — female participants · Female cross-country and biathlon skiers aged 17–27
64 mcg24 weeks15
Comparison of cheese with and without Propionibacterium freudenreichii subsp. shermanii LMGT 2951 on off-season muscle strength and VO(2) max development in Nordic skiers: a randomized clinical trial
2025 · Norvegia group — male participants · Male cross-country and biathlon skiers aged 18–25
40 mcg24 weeks15
Comparison of cheese with and without Propionibacterium freudenreichii subsp. shermanii LMGT 2951 on off-season muscle strength and VO(2) max development in Nordic skiers: a randomized clinical trial
2025 · Jarlsberg group — male participants · Male cross-country and biathlon skiers aged 18–30
77 mcg24 weeks14
Comparison of cheese with and without Propionibacterium freudenreichii subsp. shermanii LMGT 2951 on off-season muscle strength and VO(2) max development in Nordic skiers: a randomized clinical trial
2025 · Norvegia group — female participants · Female cross-country and biathlon skiers aged 17–26
33 mcg24 weeks14
Reducing Undercarboxylated Osteocalcin With Vitamin K Supplementation Does Not Promote Lean Tissue Loss or Fat Gain Over 3 Years in Older Women and Men: A Randomized Controlled Trial
2017 · Vitamin K group · Community-dwelling men and women aged 60–80 years
500 mcg3 years—
Amelioration of osteoporosis by menatetrenone in elderly female Parkinson's disease patients with vitamin D deficiency
2002 · treated group · elderly female patients with Parkinson's disease and vitamin D and K deficiencies
45 mg1 year60
Menatetrenone ameliorates osteopenia in disuse-affected limbs of vitamin D- and K-deficient stroke patients
1998 · MK-4 group · Hemiplegic patients following stroke with vitamin D and K deficiencies
45 mg1 year54
The additive effect of vitamin K supplementation and bisphosphonate on fracture risk in post-menopausal osteoporosis: a randomised placebo controlled trial
2023 · vitamin K1 arm · Post-menopausal women aged 55–85 with osteoporosis and low screening serum vitamin K1, receiving established oral bisphosphonate treatment
1 mg548 days35
The additive effect of vitamin K supplementation and bisphosphonate on fracture risk in post-menopausal osteoporosis: a randomised placebo controlled trial
2023 · MK-4 arm · Post-menopausal women aged 55–85 with osteoporosis and low screening serum vitamin K1, receiving established oral bisphosphonate treatment
45 mg548 days35
Effect of menatetrenone on bone mineral density and incidence of vertebral fractures in postmenopausal women with osteoporosis: a comparison with the effect of etidronate
2001 · M group · Postmenopausal women aged 53–78 with osteoporosis, more than 5 years after menopause
45 mg2 years23
Effect of combined administration of vitamin D3 and vitamin K2 on bone mineral density of the lumbar spine in postmenopausal women with osteoporosis
2000 · K group · Postmenopausal women aged 55–81 years with osteoporosis, more than 5 years after menopause
45 mg2 years22
Response of serum carboxylated and undercarboxylated osteocalcin to alendronate monotherapy and combined therapy with vitamin K2 in postmenopausal women
2008 · vitamin K(2) plus alendronate (group AK) · postmenopausal women with osteoporosis
45 mg1 year22
Protective effect of vitamins K2 and D3 on prednisolone-induced loss of bone mineral density in the lumbar spine
2004 · vitamin K2 alone (group K) · Patients with chronic glomerulonephritis receiving prednisolone; age and sex distribution for this arm not reported
45 mg8 weeks15
Short-term effect of vitamin K administration on prednisolone-induced loss of bone mineral density in patients with chronic glomerulonephritis
2000 · Group 2 · Patients with chronic glomerulonephritis scheduled for prednisolone treatment; age and sex not reported
45 mg10 weeks10
Vitamin K2 inhibits glucocorticoid-induced bone loss partly by preventing the reduction of osteoprotegerin (OPG)
2005 · group B · Patients with chronic glomerulonephritis starting glucocorticoid treatment; age and sex not reported
15 mg1 year10
Vitamin K2 supplementation does not influence bone loss in early menopausal women: a randomised double-blind placebo-controlled trial
2010 · MK-7 group · Healthy postmenopausal women aged 50–60 years, 1–5 years after menopause
360 mcg1 year—
Effect of Vitamin K on Vascular Health and Physical Function in Older People with Vascular Disease--A Randomised Controlled Trial
2016 · Vitamin K · Community-dwelling adults aged 70 and over with hypertension, diabetes mellitus, or previously diagnosed vascular disease; men and women
100 mcg26 weeks40
Daily vitamin K supplementation improves anticoagulant stability
2007 · vitamin K group · Patients using phenprocoumon, a vitamin K antagonist
100 mcg24 weeks—
Vitamin K1 supplementation to improve the stability of anticoagulation therapy with vitamin K antagonists: a dose-finding study
2011 · 100 μg vitamin K(1) group · Adults starting vitamin K antagonists, regardless of history of unstable anticoagulation
100 mcg1 year—
Low-Dose Daily Intake of Vitamin K(2) (Menaquinone-7) Improves Osteocalcin γ-Carboxylation: A Double-Blind, Randomized Controlled Trials
2015 · 100 μg menaquinone-7 group (Study 1) · Postmenopausal women aged 50–69 years
100 mcg4 weeks—
Low-Dose Daily Intake of Vitamin K(2) (Menaquinone-7) Improves Osteocalcin γ-Carboxylation: A Double-Blind, Randomized Controlled Trials
2015 · MK-7 group (Study 2) · Subjects aged 20–69 years; sex and health condition not specified
100 mcg12 weeks—
Vitamin K supplementation in postmenopausal women with osteopenia (ECKO trial): a randomized controlled trial
2008 · vitamin K group · Postmenopausal women with osteopenia; mean age 59 years, range 40–82
5 mg4 years217
Menatetrenone versus alfacalcidol in the treatment of Chinese postmenopausal women with osteoporosis: a multicenter, randomized, double-blinded, double-dummy, positive drug-controlled clinical trial
2014 · Group M (menatetrenone) · Women aged 45–75 years, postmenopausal for at least 5 years, with osteoporosis
45 mg1 year118
Vitamin K supplement along with vitamin D and calcium reduced serum concentration of undercarboxylated osteocalcin while increasing bone mineral density in Korean postmenopausal women over sixty-years-old
2011 · treatment group (vitamin K) · Postmenopausal Korean women over 60 years old
45 mg26 weeks40
Vitamin K2 treatment for postmenopausal osteoporosis in Indonesia
2006 · vitamin K2 group · Postmenopausal women with osteoporosis
45 mg48 weeks33
Possible site-specific effect of an intervention combining nutrition and lifestyle counselling with consumption of fortified dairy products on bone mass: the Postmenopausal Health Study II
2011 · CaDK1 group · Postmenopausal women
100 mcg1 year26
Possible site-specific effect of an intervention combining nutrition and lifestyle counselling with consumption of fortified dairy products on bone mass: the Postmenopausal Health Study II
2011 · CaDK2 group · Postmenopausal women
100 mcg1 year24
Effect of combined administration of vitamin D3 and vitamin K2 on bone mineral density of the lumbar spine in postmenopausal women with osteoporosis
2000 · DK group · Postmenopausal women aged 55–81 years with osteoporosis, more than 5 years after menopause
45 mg2 years21
Protective effect of vitamins K2 and D3 on prednisolone-induced loss of bone mineral density in the lumbar spine
2004 · vitamins D3 plus K2 (group D + K) · Patients with chronic glomerulonephritis receiving prednisolone; age and sex distribution for this arm not reported
45 mg8 weeks15
Two-year randomized controlled trial of vitamin K1 (phylloquinone) and vitamin D3 plus calcium on the bone health of older women
2007 · combined vitamins K1 and D3 plus calcium · Healthy, nonosteoporotic Scottish women aged 60 years or older
200 mcg2 years—
The effect of vitamin MK-7 on bone mineral density and microarchitecture in postmenopausal women with osteopenia, a 3-year randomized, placebo-controlled clinical trial
2021 · vitamin K2 (MK-7) group · Postmenopausal women with osteopenia
375 mcg1096 days—
The effect of menaquinone-7 supplementation on dp-ucMGP, PIVKAII, inflammatory markers, and body composition in type 2 diabetes patients: a randomized clinical trial
2022 · MK-7 group · Adults aged 20–55 years with type 2 diabetes and BMI 27–35 kg/m²; men and women
200 mcg12 weeks23
Vitamin K in breast milk: no influence of maternal dietary intake
1993 · supplemented group · Lactating mothers, 4 to 91 days postpartum
88 mcg13 weeks20
Excretion of the urinary 5C- and 7C-aglycone metabolites of vitamin K by young adults responds to changes in dietary phylloquinone and dihydrophylloquinone intakes
2007 · phylloquinone repletion diet · adults; age and health condition not specified
206 mcg10 days9
Excretion of the urinary 5C- and 7C-aglycone metabolites of vitamin K by young adults responds to changes in dietary phylloquinone and dihydrophylloquinone intakes
2007 · dihydrophylloquinone repletion diet · adults; age and health condition not specified
240 mcg10 days9
Comparison of menaquinone-4 and menaquinone-7 bioavailability in healthy women
2012 · MK-4 group, Study 2 · Healthy women aged 20–21 years
60 mcg7 days5
Comparison of menaquinone-4 and menaquinone-7 bioavailability in healthy women
2012 · MK-7 group, Study 2 · Healthy women aged 20–21 years
60 mcg7 days5
Low-dose menaquinone-7 supplementation improved extra-hepatic vitamin K status, but had no effect on thrombin generation in healthy subjects
2012 · MK-7 90 μg/day · Healthy Dutch men and women aged 18–45 years
90 mcg——
Low-dose menaquinone-7 supplementation improved extra-hepatic vitamin K status, but had no effect on thrombin generation in healthy subjects
2012 · MK-7 180 μg/day · Healthy Dutch men and women aged 18–45 years
180 mcg——
The effect of menaquinone-7 supplementation on circulating species of matrix Gla protein
2012 · 180 μg/d MK-7 supplementation group · Adults aged 40–65 years; sex and health condition not specified
180 mcg12 weeks—
Effect of a combination of genistein, polyunsaturated fatty acids and vitamins D3 and K1 on bone mineral density in postmenopausal women: a randomized, placebo-controlled, double-blind pilot study
2013 · geniVida bone blend (GBB) · Healthy postmenopausal women aged 45–55 years, 1–3 years since their last spontaneous menstrual bleeding
150 mcg26 weeks31
Vitamin K1 supplementation retards bone loss in postmenopausal women between 50 and 60 years of age
2003 · MDK group · Healthy postmenopausal women aged 50–60 years
1 mg3 years—
Effects of One-Year Menaquinone-7 Supplementation on Vascular Stiffness and Blood Pressure in Post-Menopausal Women
2025 · MK-7 · Post-menopausal women aged 40–70 with low extrahepatic vitamin K status (dp-ucMGP >400 pmol/L)
180 mcg1 year48
Vitamin K supplementation can improve stability of anticoagulation for patients with unexplained variability in response to warfarin
2007 · Vitamin K supplementation · Warfarin-treated patients with previously unstable anticoagulation control
150 mcg26 weeks35
Effect of 200μG/day of vitamin K1 on the variability of anticoagulation control in patients on warfarin: a randomized controlled trial
2013 · intervention · Adults with unstable anticoagulation control while receiving warfarin; most had venous thromboembolism
200 mcg26 weeks26
The effect of vitamin K2 supplementation on vascular calcification in haemodialysis patients: a 1-year follow-up randomized trial
2019 · vitamin K2 group · Patients on haemodialysis
200 mcg1 year22
Vitamin D(3) and vitamin K(1) supplementation of Dutch postmenopausal women with normal and low bone mineral densities: effects on serum 25-hydroxyvitamin D and carboxylated osteocalcin
2000 · vitamin K(1) · Postmenopausal women about 60 years old with normal or low bone mineral density
80 mcg1 year—
Effects of a hydrogenated form of vitamin K on bone formation and resorption
2001 · phylloquinone repletion · 15 young adults
200 mcg10 days—
Effects of a hydrogenated form of vitamin K on bone formation and resorption
2001 · dihydrophylloquinone repletion · 15 young adults
200 mcg10 days—
Vitamin K1 supplementation to improve the stability of anticoagulation therapy with vitamin K antagonists: a dose-finding study
2011 · 150 μg vitamin K(1) group · Adults starting vitamin K antagonists, regardless of history of unstable anticoagulation
150 mcg1 year—
Vitamin K1 supplementation to improve the stability of anticoagulation therapy with vitamin K antagonists: a dose-finding study
2011 · 200 μg vitamin K(1) group · Adults starting vitamin K antagonists, regardless of history of unstable anticoagulation
200 mcg1 year—
Effect of vitamin K2 supplementation on functional vitamin K deficiency in hemodialysis patients: a randomized trial
2012 · 135 μg/d menaquinone-7 group · Adults aged 18 years or older with long-term hemodialysis
135 mcg6 weeks—
Low-Dose Daily Intake of Vitamin K(2) (Menaquinone-7) Improves Osteocalcin γ-Carboxylation: A Double-Blind, Randomized Controlled Trials
2015 · 50 μg menaquinone-7 group (Study 1) · Postmenopausal women aged 50–69 years
50 mcg4 weeks—
Low-Dose Daily Intake of Vitamin K(2) (Menaquinone-7) Improves Osteocalcin γ-Carboxylation: A Double-Blind, Randomized Controlled Trials
2015 · 200 μg menaquinone-7 group (Study 1) · Postmenopausal women aged 50–69 years
200 mcg4 weeks—
No Detectable Coagulation Activation After Vitamin K (MK-7) Supplementation in Patients on Dialysis With Functional Vitamin K Deficiency: A One-Year Randomized, Placebo-Controlled Study
2024 · vitamin K (MK-7) · Patients on dialysis with functional vitamin K deficiency; age and sex not reported
360 mcg52 weeks61
The effect of menaquinone-7 (vitamin K2) supplementation on osteocalcin carboxylation in healthy prepubertal children
2009 · MK-7-supplemented group · Healthy prepubertal children; sex and age range not specified
45 mcg8 weeks28
Effect of oral water soluble vitamin K on PIVKA-II levels in newborns
1995 · oral group · Full-term, healthy, breastfed newborns
2 mg1 day24
Effect of vitamin K1 supplementation on vitamin K status in cystic fibrosis patients
1997 · vitamin K1 supplementation · Outpatients with cystic fibrosis
714 mcg4 weeks18
Effect of vitamin K2 treatment on carboxylation of osteocalcin in early postmenopausal women
2006 · vitamin K2 alone · Postmenopausal women, mean age 53, with osteopenia or osteoporosis and BMD below 0.809 g/cm2
45 mg2 years17
Plasma vitamin K1 and PIVKA-II after oral administration of mixed-micellar or cremophor EL-solubilized preparations of vitamin K1 to normal breast-fed newborns
1997 · Conventional Cremophor EL-solubilized preparation of vitamin K1 (Konakion drops) · Normal, fully breast-fed newborns
2 mg1 day16
Pharmacokinetics and efficacy of oral versus intravenous mixed-micellar phylloquinone (vitamin K1) in severe acute liver disease
2005 · oral K1 · Adults with severe acute liver disease
10 mg1 day15
Plasma vitamin K1 and PIVKA-II after oral administration of mixed-micellar or cremophor EL-solubilized preparations of vitamin K1 to normal breast-fed newborns
1997 · New mixed-micellar preparation of vitamin K1 (Konakion MM) · Normal, fully breast-fed newborns
2 mg1 day14
The effect of different meals on the absorption of stable isotope-labelled phylloquinone
2009 · Stable isotope-labelled phylloquinone capsule, given with each of the three test meals · Healthy adults aged 22–49 years, 5 women and 7 men
20 mcg1 day12
The study of bioavailability and endogenous circadian rhythm of menaquinone-7, a form of vitamin K(2,) in healthy subjects
2023 · Study II, single-dose MK-7 group · healthy male subjects; age not reported
1 mg1 day12
Improving the vitamin K status of breastfeeding infants with maternal vitamin K supplements
1997 · Stage II: mothers receiving 5 mg/d phylloquinone · Lactating mothers of human milk-fed infants; ages and health condition not specified
5 mg12 weeks11
Effect of phylloquinone (vitamin K1) supplementation for 12 months on the indices of vitamin K status and bone health in adult patients with Crohn's disease
2014 · 1000 μg phylloquinone group (dose-ranging RCT) · Adults with Crohn's disease, currently in remission
1 mg2 weeks10
Effect of phylloquinone (vitamin K1) supplementation for 12 months on the indices of vitamin K status and bone health in adult patients with Crohn's disease
2014 · 2000 μg phylloquinone group (dose-ranging RCT) · Adults with Crohn's disease, currently in remission
2 mg2 weeks10
Improving the vitamin K status of breastfeeding infants with maternal vitamin K supplements
1997 · Stage I: mothers receiving 2.5 mg/d phylloquinone · Lactating mothers; ages and health condition not specified
2.5 mg6 weeks10
Improving the vitamin K status of breastfeeding infants with maternal vitamin K supplements
1997 · Stage I: mothers receiving 5.0 mg/d phylloquinone · Lactating mothers; ages and health condition not specified
5 mg6 weeks10
Menaquinone-4 in breast milk is derived from dietary phylloquinone
2002 · 0.8 mg/d phylloquinone group · Lactating mothers with a full-term healthy infant
800 mcg12 days8
Menaquinone-4 in breast milk is derived from dietary phylloquinone
2002 · 2.0 mg/d phylloquinone group · Lactating mothers with a full-term healthy infant
2 mg12 days8
Menaquinone-4 in breast milk is derived from dietary phylloquinone
2002 · 4.0 mg/d phylloquinone group · Lactating mothers with a full-term healthy infant
4 mg12 days7
Comparison of menaquinone-4 and menaquinone-7 bioavailability in healthy women
2012 · MK-4 group, Study 1 · Healthy women aged 20–21 years
420 mcg1 day5
Comparison of menaquinone-4 and menaquinone-7 bioavailability in healthy women
2012 · MK-7 group, Study 1 · Healthy women aged 20–21 years
420 mcg1 day5
The study of bioavailability and endogenous circadian rhythm of menaquinone-7, a form of vitamin K(2,) in healthy subjects
2023 · Study I, single-dose MK-7 group · healthy male subjects; age not reported
1 mg1 day5
Response of vitamin K status to different intakes and sources of phylloquinone-rich foods: comparison of younger and older adults
1999 · broccoli diet · younger and older adult men and women
377 mcg5 days—
Response of vitamin K status to different intakes and sources of phylloquinone-rich foods: comparison of younger and older adults
1999 · oil diet · younger and older adult men and women
417 mcg5 days—
Intestinal absorption of mixed micellar phylloquinone (vitamin K1) is unreliable in infants with conjugated hyperbilirubinaemia: implications for oral prophylaxis of vitamin K deficiency bleeding
2003 · oral group · Infants younger than 6 months with conjugated hyperbilirubinaemia
2 mg1 day—
Effects of oral and intramuscular vitamin K prophylaxis on vitamin K1, PIVKA-II, and clotting factors in breast fed infants
1992 · Oral vitamin K1 group · Healthy breast-fed infants given prophylaxis at birth
1 mg1 day—
Efficacy of high dose phylloquinone in correcting vitamin K deficiency in cystic fibrosis
2008 · 1 mg/day vitamin K1 · Children aged 8–18 years with pancreatic-insufficient cystic fibrosis
1 mg30 days—
Efficacy of high dose phylloquinone in correcting vitamin K deficiency in cystic fibrosis
2008 · 5 mg/day vitamin K1 · Children aged 8–18 years with pancreatic-insufficient cystic fibrosis
5 mg30 days—
Low-dose menaquinone-7 supplementation improved extra-hepatic vitamin K status, but had no effect on thrombin generation in healthy subjects
2012 · MK-7 10 μg/day · Healthy Dutch men and women aged 18–45 years
10 mcg——
Low-dose menaquinone-7 supplementation improved extra-hepatic vitamin K status, but had no effect on thrombin generation in healthy subjects
2012 · MK-7 20 μg/day · Healthy Dutch men and women aged 18–45 years
20 mcg——
Low-dose menaquinone-7 supplementation improved extra-hepatic vitamin K status, but had no effect on thrombin generation in healthy subjects
2012 · MK-7 45 μg/day · Healthy Dutch men and women aged 18–45 years
45 mcg——
Low-dose menaquinone-7 supplementation improved extra-hepatic vitamin K status, but had no effect on thrombin generation in healthy subjects
2012 · MK-7 360 μg/day · Healthy Dutch men and women aged 18–45 years
360 mcg——
The effect of menaquinone-7 supplementation on circulating species of matrix Gla protein
2012 · 360 μg/d MK-7 supplementation group · Adults aged 40–65 years; sex and health condition not specified
360 mcg12 weeks—
Vitamin K2 supplementation improves hip bone geometry and bone strength indices in postmenopausal women
2007 · MK-4 group · Postmenopausal women aged 55–75 years, apparently healthy and non-osteoporotic
45 mg3 years161
Short-term menatetrenone therapy increases gamma-carboxylation of osteocalcin with a moderate increase of bone turnover in postmenopausal osteoporosis: a randomized prospective study
2009 · menatetrenone group · Postmenopausal patients with osteoporosis
45 mg26 weeks56
The effect of vitamin K4 supplementation on insulin resistance in individuals with type 2 diabetes: a double-blind randomised placebo-controlled clinical trial
2023 · Vitamin K group · Adults aged 18–65 with type 2 diabetes
1 mg24 weeks45
Six weeks phylloquinone supplementation produces undesirable effects on blood lipids with no changes in inflammatory and fibrinolytic markers in postmenopausal women
2008 · phylloquinone · postmenopausal women
500 mcg6 weeks31
Oral vitamin K lowers the international normalized ratio more rapidly than subcutaneous vitamin K in the treatment of warfarin-associated coagulopathy. A randomized, controlled trial
2002 · Oral vitamin K · Patients with warfarin-associated coagulopathy and INR 4.5–10.0
1 mg1 day26
Low-dose vitamin K2 (MK-4) supplementation for 12 months improves bone metabolism and prevents forearm bone loss in postmenopausal Japanese women
2014 · 1.5-mg MK-4 group · Postmenopausal Japanese women aged 50–65 years
1.5 mg1 year24
Dietary phylloquinone depletion and repletion in postmenopausal women: effects on bone and mineral metabolism
2006 · Phylloquinone repletion · Postmenopausal women, mean age 70 years
450 mcg12 weeks21
Effect of phylloquinone supplementation on glucose homeostasis in humans
2010 · experimental group · Community-dwelling postmenopausal women
1 mg1 year21
Effect of low dose vitamin K2 (MK-4) supplementation on bio-indices in postmenopausal Japanese women
2009 · MK-4 group · Healthy postmenopausal Japanese women aged 53–65 years
1.5 mg4 weeks20
Effect of vitamin K supplementation on serum calcification propensity and arterial stiffness in vitamin K-deficient kidney transplant recipients: A double-blind, randomized, placebo-controlled clinical trial
2023 · vitamin K2 · Vitamin K-deficient kidney transplant recipients
360 mcg12 weeks20
Effect of dietary fat content on oral bioavailability of menatetrenone in humans
1996 · Menatetrenone after meals with varied fat content · Healthy male volunteers; age not reported
15 mg1 day18
Phytomenadione or menadiol in the management of an elevated international normalized ratio (prothrombin time)
2000 · oral menadiol · Patients with cholestasis and an international normalized ratio greater than 1.2
20 mg3 days12
Reversal of excessive effect of regular anticoagulation: low oral dose of phytonadione (vitamin K1) compared with warfarin discontinuation
1993 · group B · Patients with INR >5 and no bleeding complications; age and sex not reported
2 mg1 day11
The effect of dietary vitamin K on warfarin-induced anticoagulation
1991 · habitual diet supplemented with phytomenadione · Patients on stable anticoagulant treatment
1 mg—5
Randomized, placebo-controlled trial of oral phytonadione for excessive anticoagulation
2000 · phytonadione · Nonbleeding patients with excessive anticoagulation and INR 6.0–10.0
2.5 mg1 day—
Vitamin K supplementation reduces serum concentrations of under-gamma-carboxylated osteocalcin in healthy young and elderly adults
2000 · phylloquinone · Healthy adults aged 18–30 years and 65 years or older, approximately equally distributed by sex
1 mg2 weeks—
Effects of oral vitamin K on S- and R-warfarin pharmacokinetics and pharmacodynamics: enhanced safety of warfarin as a CYP2C9 probe
2001 · warfarin plus vitamin K · healthy adults who were CYP2C9*1 homozygotes
10 mg1 day—
A high phylloquinone intake is required to achieve maximal osteocalcin gamma-carboxylation
2002 · Substudy B: 250-micro-g phylloquinone group · Healthy women and men aged 19–36 years
250 mcg2 weeks—
A high phylloquinone intake is required to achieve maximal osteocalcin gamma-carboxylation
2002 · Substudy B: 375-micro-g phylloquinone group · Healthy women and men aged 19–36 years
375 mcg2 weeks—
A high phylloquinone intake is required to achieve maximal osteocalcin gamma-carboxylation
2002 · Substudy B: 500-micro-g phylloquinone group · Healthy women and men aged 19–36 years
500 mcg2 weeks—
A high phylloquinone intake is required to achieve maximal osteocalcin gamma-carboxylation
2002 · Substudy B: 1000-micro-g phylloquinone group · Healthy women and men aged 19–36 years
1 mg2 weeks—
Vitamin K₂ alters bone metabolism markers in hemodialysis patients with a low serum parathyroid hormone level
2011 · vitamin K₂ group · Hemodialysis patients with low intact PTH levels (<100 pg/ml)
45 mg1 year—
Effect of vitamin K2 supplementation on functional vitamin K deficiency in hemodialysis patients: a randomized trial
2012 · 45 μg/d menaquinone-7 group · Adults aged 18 years or older with long-term hemodialysis
45 mcg6 weeks—
Effect of vitamin K2 supplementation on functional vitamin K deficiency in hemodialysis patients: a randomized trial
2012 · 360 μg/d menaquinone-7 group · Adults aged 18 years or older with long-term hemodialysis
360 mcg6 weeks—
PIVKA-II plasma levels as markers of subclinical vitamin K deficiency in term infants
2012 · G I (25 μg/die vitamin K) · Term, exclusively breast-fed newborns
25 mcg60 days—
PIVKA-II plasma levels as markers of subclinical vitamin K deficiency in term infants
2012 · G II (12 μg/die vitamin K) · Term, exclusively breast-fed newborns
12 mcg60 days—
Effects of Vitamin K on Matrix Metalloproteinase-3 and Rheumatoid Factor in Women with Rheumatoid Arthritis: A Randomized, Double-Blind, Placebo-Controlled Trial
2016 · Vitamin K1 group · Women with rheumatoid arthritis
10 mg8 weeks—
Glycemic control improvement in individuals with type 2 diabetes with vitamin K(2) supplementation: a randomized controlled trial
2021 · vitamin K 2 group · insulin-independent people with type 2 diabetes mellitus
360 mcg12 weeks—
The effect of vitamin K1 on arterial calcification activity in subjects with diabetes mellitus: a post hoc analysis of a double-blind, randomized, placebo-controlled trial
2022 · vitamin K1 supplementation · Individuals with diabetes mellitus and established coronary calcification (coronary calcium score > 10), without clinical coronary artery disease
10 mg90 days—
The Contribution of Lipids to the Interindividual Response of Vitamin K Biomarkers to Vitamin K Supplementation
2019 · treatment group · Men and women aged 60–80 years, generally in good health and free of known coronary disease or osteoporosis
500 mcg3 years229
Effect of vitamin K2 treatment on carboxylation of osteocalcin in early postmenopausal women
2006 · vitamin K2 plus vitamin D3 · Postmenopausal women, mean age 53, with osteopenia or osteoporosis and BMD below 0.809 g/cm2
45 mg2 years17
Vitamin D(3) and vitamin K(1) supplementation of Dutch postmenopausal women with normal and low bone mineral densities: effects on serum 25-hydroxyvitamin D and carboxylated osteocalcin
2000 · vitamins K(1)+D(3) · Postmenopausal women about 60 years old with normal or low bone mineral density
80 mcg1 year—
Effect of phylloquinone supplementation on biochemical markers of vitamin K status and bone turnover in postmenopausal women
2007 · 200 microg phylloquinone/d · Postmenopausal women
200 mcg6 weeks—
Effect of phylloquinone supplementation on biochemical markers of vitamin K status and bone turnover in postmenopausal women
2007 · 500 microg phylloquinone/d · Postmenopausal women
500 mcg6 weeks—
Placental transfer of vitamin K1 in preterm pregnancy
1990 · Vitamin K1 treatment group · Women before 35 weeks’ gestation with premature rupture of membranes and/or preterm labor
20 mg——
Vitamin K supplementation and progression of coronary artery calcium in older men and women
2009 · treatment · Healthy older men and postmenopausal women
500 mcg3 years200
Effect of phylloquinone (vitamin K1) supplementation for 12 months on the indices of vitamin K status and bone health in adult patients with Crohn's disease
2014 · 1000 μg vitamin K/d plus calcium and vitamin D3 group (main RCT) · Adults with Crohn's disease, currently in remission
1 mg1 year43
Supplementation with Octacosanol Affects the Level of PCSK9 and Restore Its Physiologic Relation with LDL-C in Patients on Chronic Statin Therapy
2021 · dietary supplement group · Adults aged 40–80 years with hypercholesterolemia or mixed dyslipidaemia, taking atorvastatin chronically
45 mcg13 weeks42
Assessment of vitamin A, vitamin B(2), vitamin B(12), vitamin K, folate, and choline status following 4 months of multinutrient supplementation in healthy vegans: a randomised, double-blind, placebo-controlled trial
2025 · INT (intervention group; standard and double omega-3 dosage subgroups) · Healthy adults aged 18 years or older who had followed a vegan diet for at least 1 year; no diagnosed vitamin or mineral deficiency
50 mcg120 days35
The effects of vitamin D, K and calcium co-supplementation on carotid intima-media thickness and metabolic status in overweight type 2 diabetic patients with CHD
2016 · vitamin D, vitamin K and calcium supplements · Overweight patients with type 2 diabetes and CHD; age and sex not specified
180 mcg12 weeks33
Reduced bone resorption by intake of dietary vitamin D and K from tailor-made Atlantic salmon: A randomized intervention trial
2016 · HD/HK · Postmenopausal women aged 50–65 years
23.1 mcg12 weeks31
Reduced bone resorption by intake of dietary vitamin D and K from tailor-made Atlantic salmon: A randomized intervention trial
2016 · HD/LK · Postmenopausal women aged 50–65 years
1.37 mcg12 weeks31
The Effects of Vitamin D-K-Calcium Co-Supplementation on Endocrine, Inflammation, and Oxidative Stress Biomarkers in Vitamin D-Deficient Women with Polycystic Ovary Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial
2016 · vitamin D-K-calcium co-supplementation group · Vitamin D-deficient women aged 18–40 years with polycystic ovary syndrome
180 mcg8 weeks30
Reduced bone resorption by intake of dietary vitamin D and K from tailor-made Atlantic salmon: A randomized intervention trial
2016 · LD/HK · Postmenopausal women aged 50–65 years
23.1 mcg12 weeks30
The Effects of Calcium, Vitamins D and K co-Supplementation on Markers of Insulin Metabolism and Lipid Profiles in Vitamin D-Deficient Women with Polycystic Ovary Syndrome
2017 · calcium, vitamin D and vitamin K group · Women aged 18–40 years with vitamin D deficiency and polycystic ovary syndrome
180 mcg8 weeks28
Vitamin K(2) (menaquinone 4) reduces serum undercarboxylated osteocalcin level as early as 2 weeks in elderly women with established osteoporosis
2003 · MK(4) group · Elderly women with established osteoporosis and vertebral fractures
45 mg2 weeks—
Effect of calcium, vitamins K1 and D3 on bone in galactosemia
2006 · calcium, vitamins K1 and D3 supplementation · Children aged 3–17 years with classical galactosemia
1 mg2 years—
Effect of calcium fortified milk supplementation with or without vitamin K on biochemical markers of bone turnover in premenopausal women
2006 · High calcium skim milk with added phylloquinone · Premenopausal women aged 20 to 35 years
80 mcg16 weeks—
Effect of vitamin K supplementation on insulin resistance in older men and women
2008 · Vitamin K–treated group · Men and postmenopausal women aged 60–80 without diabetes
500 mcg3 years—
Vitamin K2 (menaquinone-7) increases plasma adiponectin but does not affect insulin sensitivity in postmenopausal women: a randomized controlled trial
2021 · MK-7 group · Postmenopausal women; the abstract describes them as healthy
375 mcg1 year—
Vitamin K2 and D in Patients With Aortic Valve Calcification: A Randomized Double-Blinded Clinical Trial
2022 · MK-7 plus vitamin D · Elderly men with an aortic valve calcification score >300 AU
720 mcg2 years—
Effects of vitamin K2 and D3 supplementation on epicardial adipose tissue and systemic inflammation: A substudy of the AVADEC trial
2025 · vitamin K2 and D3 group · Men aged 65–74 at cardiovascular risk
720 mcg2 years—
Randomised Controlled Trial of Nutritional Supplement on Bone Turnover Markers in Indian Premenopausal Women
2021 · test group · Premenopausal Indian women aged 25–45 years in good general health, with BMI 18–30 kg/m²
55 mcg180 days57
Nutritional supplementation of hop rho iso-alpha acids, berberine, vitamin D₃, and vitamin K₁ produces a favorable bone biomarker profile supporting healthy bone metabolism in postmenopausal women with metabolic syndrome
2011 · intervention arm · Postmenopausal women with metabolic syndrome
1 mg14 weeks25
Hop rho iso-alpha acids, berberine, vitamin D3 and vitamin K1 favorably impact biomarkers of bone turnover in postmenopausal women in a 14-week trial
2010 · treatment arm · Healthy postmenopausal women
1 mg14 weeks16
Osteocalcin carboxylation is not associated with body weight or percent fat changes during weight loss in post-menopausal women
2015 · Caloric restriction-only group (CR) · Sedentary post-menopausal women aged 50–70 years with overweight or obesity (BMI 25–40 kg/m²)
80 mcg20 weeks—
Osteocalcin carboxylation is not associated with body weight or percent fat changes during weight loss in post-menopausal women
2015 · Moderate-intensity exercise group · Sedentary post-menopausal women aged 50–70 years with overweight or obesity (BMI 25–40 kg/m²)
80 mcg20 weeks—
Osteocalcin carboxylation is not associated with body weight or percent fat changes during weight loss in post-menopausal women
2015 · Vigorous-intensity exercise group · Sedentary post-menopausal women aged 50–70 years with overweight or obesity (BMI 25–40 kg/m²)
80 mcg20 weeks—